Document is current

Article History

Received: 11 January 2025

Accepted: 10 February 2025

First Online: 28 February 2025

Declarations

:

: Kevin Fernando has received speaker fees from AstraZeneca, Bayer, Boehringer Ingelheim, Dexcom, Daiichi Sankyo, Lilly, Menarini, Idorsia, Thornton & Ross, and Boston Scientific; consultancy fees from AstraZeneca, Dexcom, Boehringer Ingelheim, Lilly, Menarini, Roche, Ovivia, Idorsia, and Grunenthal; he has also received conference registration & subsistence from Menarini, Daiichi Sankyo, and Lilly. Vicki Alabraba has received honoraria from Dexcom, NovoNordisk, Eli Lilly, Sanofi, Menarini, Roche, and AstraZeneca; her current affiliation is with Insulet, Inc. John B. Welsh is an employee of Dexcom, Inc. Samuel Seidu reports personal fees from Amgen, AstraZeneca, Napp Pharmaceuticals, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Roche, Sanofi, and Boehringer Ingelheim. Abbott, Dexcom, and Daiichi Sankyo; additionally, he reports grants from AstraZeneca, Sanofi, Servier, and Janssen. W. David Strain has been awarded research grants from Takeda, Novo Nordisk and Novartis, and has received support from the National Institute for Health Research (NIHR) Exeter Clinical Research Facility and the NIHR Collaboration for Leadership in Applied Health Research and Care (CLAHRC) for the South West Peninsula; he has also participated in speaker bureaus sponsored by AstraZeneca, Bayer, Boehringer Ingelheim, MSD, Napp, Novartis, Novo Nordisk, and Takeda. W. David Strain is an Editorial Board member of Diabetes Therapy. W. David Strain was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial revisions. Heather Elizabeth Bell received honoraria and sponsorship from Abbott, Boehringer Ingelheim, Dexcom, Novo Nordisk, Napp, AstraZeneca, Daiichi Sankyo, and Roche. Sarah Davies has received fees from Abbott, Boehringer Ingelheim, Dexcom, Lilly, Menarini, Novo Nordisk, AstraZeneca, Daiichi Sankyo, and Roche. Marc Evans has received honoraria and research awards from Novo Nordisk, AstraZeneca, BI, Sunovion, and Novartis. Marc Evans is an Editor-in-Chief of Diabetes Therapy. Marc Evans was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. The authors thank Dexcom for travel grants and meeting support.

: This article is based on previously conducted studies and expert opinion. It does not contain any studies with human participants or animals performed by any of the authors.